Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Equipment >

Cytosorbents Corporation (CTSOD)

Add CTSOD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator The_Free_Nebula, BuyMyAsk, dr_lowenstein
Search This Board:
Last Post: 12/19/2014 11:13:00 PM - Followers: 178 - Board type: Free - Posts Today: 0
About CytoSorbents, CytoSorb, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, allowing it to be sold throughout the European Union (E.U.) under the CE Mark, to be used in clinical situations where cytokines are elevated. The goal of the CytoSorb® cytokine filter is to reduce "cytokine storm" in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. The CytoSorb® filter has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany, Austria and Switzerland for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website:


CytoSorb® - A First-in-Class Cytokine Filter Approved in the European Union


CytoSorb® is a potentially breakthrough critical care immunotherapy that attempts to address one of the most challenging unmet medical needs in medicine…the ability to prevent or mitigate multiple organ failure - the leading cause of death in the intensive care unit (ICU) from any cause.

In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts and produces a massive excess of cytokines, or “cytokine storm”. Cytokines normally help the body cope with injury, but at these levels, cytokine storm is toxic to the body, driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure and often death. It follows that reduction of cytokine storm may limit this cascade of events, thereby reducing the severity of illness, and helping patients recover and survive. Until recently, however, there were no effective ways to reduce cytokine storm broadly.

CytoSorb® is a first-in-class extracorporeal cytokine filter, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated. It is compatible with standard hemodialysis machines and blood pumps found in most hospitals. Blood is pumped out of the body, through the CytoSorb® cartridge that contains the company’s proprietary blood compatible porous polymer beads, and the “purified” blood is recirculated back to the patient. In a six hour period, a patient's entire blood volume can be treated approximately 20 times.

CytoSorb® is clinically proven to reduce cytokine storm in the company's multi-center, randomized, controlled European Sepsis Trial conducted in Germany. Treatment was safe and well-tolerated in more than 300 human treatments in very sick patients with the worst forms of sepsis and lung injury, and treatment has been safe in nearly 1,500 human treatments overall. Early data suggests that CytoSorb® can reduce organ injury and improve survival in patients at high risk of cytokine injury, particularly those patients with very high cytokine levels, and patients older than age 65.

CytoSorb® has now been used successfully in many conditions where deadly inflammation can lead to organ injury and failure. We are seeing strong interest in the following clinical applications:


There are more than 100 key opinion leaders in Germany, Austria, and Switzerland (our direct sales territories) who are either using or committed to using CytoSorb in clinical practice or clinical studies. More than 30 investigator-initiated studies in a diverse set of applications are being planned, with many already enrolling patients. In the United States, the U.S. Air Force is funding a 30-patient, FDA-approved randomized controlled human trauma pilot study.

As these other independent studies progress, CytoSorbents collaborates with Dr. John Kellum at the University of Pittsburgh Medical Center, and is sponsoring clinical studies in the area of severe sepsis and septic shock, the result of an overzealous immune response to a severe infection such as pneumonia or a ruptured appendix. Severe sepsis and septic shock are collectively a top ten cause of death worldwide, afflicting approximately 27 million people annually, killing approximately 1 in 3 patients despite the best medical care. CytoSorbents is conducting clinical trials in Europea and currently has an FDA-approved IDE application to run a small sepsis trial in the U.S.. The company will look to conduct a U.S. pivotal sepsis study in the future as a key step towards U.S. FDA approval.

Because of the versatility of CytoSorb®, there are many other potential applications of the technology outside of critical care medicine as well. In particular, CytoSorb® has been used many times intraoperatively during open heart surgery, where the heart must be stopped in order to operate on it, while the blood is pumped outside of the body by a heart-lung machine that oxygenates the blood and pumps it back to the rest of the body. This procedure can result in the production of inflammatory mediators such as cytokines, as well as hemolysis and the release of free hemoglobin into the blood. This can result in inflammation and post-operative complications such as failure to wean from mechanical ventilation and kidney failure. There are more than 1 million open heart surgeries each year in the U.S. and E.U. combined, with an addressable market of more than $1 billion for CytoSorb®.

Another application is in cancer immunotherapy. Cancer cachexia is a wasting condition that occurs in most cancers that leads to rapid uncontrolled weight loss, anorexia, and physical debilitation. Patients lose the physical reserve needed to tolerate treatment and fight the cancer. Because CytoSorb® can remove a broad range of cytokines and other inflammatory mediators that drive cancer cachexia, it may be very helpful in this condition. CytoSorbents is exploring this application, as well as the use of CytoSorb® as a primary cancer immunotherapy to kickstart the immune system to attack cancer, with researchers at the University of Pennsylvania School of Veterinary Medicine.

CytoSorb® is being sold for clinical use in the European Union and in countries outside of the European Union that accept European CE Mark approval such as India, Russia, Turkey and others. The total addressable market for CytoSorb® in critical care applications such as sepsis, burn injury, trauma, ARDS, pancreatitis and other diseases is estimated at $10-15 Billion in the U.S. and Europe alone.


From Shareholder's Letter

Goals for 2014

We have laid out an ambitious, yet potentially achievable, agenda for the next two years. Some of our highest priorities are:

  • Greater awareness of our story and technology through increased media exposure and improved investor relations
  • Revenue growth and increased product adoption in our direct sales territories
  • Distributor agreements for CytoSorb in Europe and elsewhere
  • Strategic partnerships for our pipeline products
  • Non-dilutive funding from grants and other programs
  • Commencement of a U.S. based trial
  • Clinical data and new clinical applications with data being presented at key scientific conferences
  • Improving liquidity and institutional sponsorship of our stock with potential up-listing to a national stock exchange

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTSO News: CytoSorbents Reports Temporary Change of Stock Trading Symbol 12/05/2014 08:00:00 PM
CTSO News: /C O R R E C T I O N -- CytoSorbents Corporation/ 12/05/2014 03:37:00 PM
CTSO News: CytoSorbents Teams with Smart Medical Solutions to Distribute CytoSorb® in Romania and Moldova 12/05/2014 08:00:00 AM
CTSO News: Current Report Filing (8-k) 12/04/2014 09:07:08 AM
CTSO News: Current Report Filing (8-k) 12/02/2014 08:26:11 AM
#6179   I agree with BMA. Holding the recent gains dah174174 12/19/14 11:13:00 PM
#6178   Great article, especially after reading slide 5 of orangecat 12/19/14 09:28:13 PM
#6177   The Fires Within andy55q 12/19/14 05:51:59 PM
#6176   This was a good close today. Volume BuyMyAsk 12/19/14 05:01:33 PM
#6175   If I missed anything important please let me orangecat 12/19/14 11:06:26 AM
#6174   From Yahoo MB-Updated Cytosorbents Overview andy55q 12/19/14 10:40:16 AM
#6173   The correct argument lies in-between both of your BuyMyAsk 12/19/14 09:36:42 AM
#6172   Laker5, What are you doing here? AEMD has andy55q 12/19/14 08:33:22 AM
#6171   You are incorrect. Rapid emerging growth companies are dah174174 12/19/14 08:30:28 AM
#6170   You are incorrect. Rapid emerging growth companies are dah174174 12/19/14 08:30:14 AM
#6169   CTSO now too thinly traded to attract serious laker5 12/19/14 07:54:40 AM
#6168   CTSO market cap $170 million, sales not near laker5 12/19/14 07:49:15 AM
#6167   Seems the Aethelon filter did not help the garydaemon 12/18/14 11:06:30 PM
#6166   Thank you, I appreciate you sharing your wisdom. IL-6 12/18/14 07:36:09 PM
#6165   Dr. L do you have any thoughts and/or BuyMyAsk 12/18/14 05:25:58 PM
#6164   My feeling.. it was simply overexuberance at the dah174174 12/18/14 04:49:32 PM
#6163   I understand what you are trying to say. BuyMyAsk 12/18/14 04:28:22 PM
#6162   Never mind, you are missing the point. andy55q 12/18/14 04:22:20 PM
#6161   Size of company is not based on revenue. BuyMyAsk 12/18/14 04:14:36 PM
#6160   Go over and take a look at the andy55q 12/18/14 04:08:45 PM
#6159   Guy - what does this even mean? BuyMyAsk 12/18/14 03:58:59 PM
#6158   AVNR is another M Cap 3.3 billion andy55q 12/18/14 03:53:27 PM
#6157   Take a look at ACAD, 3.2 billion market andy55q 12/18/14 03:50:03 PM
#6156   The reason that happened is because the ASK BuyMyAsk 12/18/14 03:23:47 PM
#6155   Dah174174, you worked on Wall Street if I IL-6 12/18/14 01:55:10 PM
#6154   The company is too small and the company BuyMyAsk 12/18/14 12:53:40 PM
#6153   Still that should add some pressure to the ask. vinovista 12/18/14 12:25:53 PM
#6152   Didn't the CEO state that many investment funds Paulness 12/18/14 12:07:52 PM
#6151   It is only going to be micro-cap based BuyMyAsk 12/18/14 11:40:30 AM
#6150   Yes it is The_Free_Nebula 12/18/14 11:39:01 AM
#6149   When will the mutual funds need to get vinovista 12/18/14 11:35:16 AM
#6148   To make an apples to apples comparison... Duh! BuyMyAsk 12/18/14 11:33:30 AM
#6147   Why do you need to adjust? The split emmagene 12/18/14 11:14:15 AM
#6146   Great ending to 2014... The_Free_Nebula 12/18/14 11:07:26 AM
#6145   I completely agree. Over 2M shares traded BuyMyAsk 12/18/14 10:21:47 AM
#6144   looking so nice. Believed 12/18/14 10:03:14 AM
#6143   Starts trading on NASDAQ Dec. 23...was announced today dah174174 12/18/14 10:01:36 AM
#6142   This is certainly a milestone for the company, BuyMyAsk 12/18/14 09:15:38 AM
#6141   It starts trading under NASDAQ Tuesday. Maybe later? January? TheDane 12/18/14 09:05:52 AM
#6140   Thanks Dane! Congratulations everybody! CTSO is now a bkmomail 12/18/14 08:34:31 AM
#6139   CTSO gets NASDAQ, TheDane 12/18/14 07:05:40 AM
#6138   Here are the final numbers for the ebola andy55q 12/17/14 05:28:26 PM
#6137   +Mass Device andy55q 12/17/14 05:24:40 PM
#6136   Good due diligence. That gives them enough BuyMyAsk 12/17/14 01:47:23 PM
#6134   CTSOD began trading Dec 5. NASDAQ requires 20 bkmomail 12/17/14 01:43:04 PM
#6133   If I was the ceo I wouldn't take Paulness 12/17/14 01:35:47 PM
#6132   I would be fine with a buyout as BuyMyAsk 12/17/14 01:29:54 PM
#6131   My biggest fear is that the CEO screws SABAI 12/17/14 01:18:08 PM
#6130   I really hope when we up list this BuyMyAsk 12/17/14 01:06:14 PM
#6129   I believe that means that the board has eColi 12/17/14 12:24:14 PM